Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

Khosravan Reza; Motzer Robert J.; Fumagalli Elena; Rini Brian I.

首页> 外文期刊>Clinical pharmacokinetics >Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

【24h】

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

机译：晚期肾细胞癌或胃肠道间质瘤患者的给药方案对舒尼替尼的群体药代动力学/药效学建模

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Sunitinib is a multi-targeted tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma (RCC) and imatinib-resistant/intolerant gastrointestinal stromal tumors (GIST).

机译：背景技术舒尼替尼是一种多靶点酪氨酸激酶抑制剂，用于治疗晚期肾细胞癌（RCC）和伊马替尼耐药/不能耐受的胃肠道间质瘤（GIST）。

著录项

来源
《Clinical pharmacokinetics 》 |2016年第10期| 共19页
作者
Khosravan Reza; Motzer Robert J.; Fumagalli Elena; Rini Brian I.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor [J] . Khosravan Reza, Motzer Robert J., Fumagalli Elena, Clinical pharmacokinetics . 2016 ,第10期

机译：晚期肾细胞癌或胃肠道间质瘤患者的给药方案对舒尼替尼的群体药代动力学/药效学建模
2. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor [J] . Khosravan Reza, Motzer Robert J., Fumagalli Elena, Clinical pharmacokinetics . 2016 ,第10期

机译：晚期肾细胞癌或胃肠道肿瘤患者用量表的孙尼替尼的人口药代动力学/药效模型
3. POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF SUNITINIB (SU) IN GASTROINTESTINAL STROMAL TUMOR (GIST) AND RENAL CELL CARCINOMA (RCC) PATIENTS [J] . Khosravan R., Mugundu G. M., Casali P. G., Clinical Pharmacology and Therapeutics . 2014 ,第Suppla1期

机译：SUNITINIB（SU）在胃肠道间质瘤（GIST）和肾细胞癌（RCC）患者中的种群药动学和药代动力学模型
4. New DCE-MRI parameters to quantify the vascular changes induced by sunitinib treatment in renal carcinoma tumors [C] . Al-Bashir Areen K., Hillman Gilda G., Li Meng, Middle East Conference on Biomedical Engineering . 2014

机译：新的DCE-MRI参数可量化舒尼替尼治疗在肾癌肿瘤中诱导的血管变化
5. Beta-lactam antimicrobial dosing optimization in obese patients compared to non-obese patients using population pharmacokinetic/pharmacodynamic approach. [D] . Chung, Eun Kyoung. 2015

机译：使用群体药代动力学/药效学方法，与非肥胖患者相比，肥胖患者的β-内酰胺抗菌药物剂量优化。
6. PopulationPharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patientswith Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor [O] . Reza Khosravan, Robert J. Motzer, Elena Fumagalli, -1

机译：人口舒尼替尼在患者中的给药方案的药代动力学/药效学模型晚期肾细胞癌或胃肠道间质瘤
7. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor [O] . Reza Khosravan, Robert J. Motzer, Elena Fumagalli, 2016

机译：晚期肾细胞癌或胃肠道间质瘤患者的给药方案对舒尼替尼的群体药代动力学/药效学建模

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

摘要

著录项

相似文献

相关主题

期刊订阅